Related Experiment Video
Updated: Jun 22, 2026
06:55
Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
Validity of perinatal pharmacoepidemiologic studies using data from the RAMQ administrative database.
1Faculty of Pharmacy, University of Montreal, Montreal, Canada, 2Research Center, CHU Sainte-Justine, Montreal, Canada. anick.berard@umontreal.ca
Summary
The Quebec prescription claims database (RAMQ-Rx) captures pregnant women who are younger, more likely to be immigrants, and have lower incomes compared to privately insured individuals. These demographic differences impact the generalizability of RAMQ-Rx data in perinatal studies.
Area of Science:
- Perinatal pharmacoepidemiology
- Health services research
- Population health
Background:
- The Quebec prescription claims database (RAMQ-Rx) is frequently utilized for perinatal pharmacoepidemiologic research.
- Concerns exist regarding the generalizability of findings from RAMQ-Rx data to diverse patient populations.
Purpose of the Study:
- To compare demographic and socioeconomic characteristics of pregnant women covered by the RAMQ-Rx versus those with private drug insurance.
Main Methods:
- A prospective study was conducted from October 2004 to March 2006 at the University of Montreal affiliated clinics.
- Eligible participants were pregnant women aged 18+, within 16 weeks of gestation, and proficient in English or French.
- A self-administered questionnaire was used to collect data.
Main Results:
- Out of 363 women, 99 (27%) had RAMQ-Rx coverage and 264 (73%) had private insurance.
- RAMQ-Rx insured women were younger (30.7 vs. 32.1 years), more likely to be immigrants (60% vs. 24%), and have incomes below poverty level (39% vs. 2%).
- RAMQ-Rx users were less likely to be Caucasian (69% vs. 86%), employed (51% vs. 87%), and have post-secondary education (76% vs. 95%).
Conclusions:
- Significant demographic and socioeconomic disparities exist between pregnant women with RAMQ-Rx and private insurance.
- These differences may limit the external validity (generalizability) of studies using RAMQ-Rx data.
- The internal validity of studies utilizing RAMQ-Rx data is not expected to be compromised.
Related Concept Videos
01:19Pharmacovigilance
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
01:12Analysis of Population Pharmacokinetic Data
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...